🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At #CUAnschutz, you are limited only by what you can imagine. We're turning your dreams into life-changing discoveries to change the face of medicine, together. ✨ This is where dreams live. Discover more at cuanschutz.edu/dreams.

The dark zone of CNS relapse in DLBCL ashpublications.org/blood/article/… @BloodJournal

Just out Blood Journal : Outcome of #CART therapy for #burkitt #lymphoma. Another great internatioal collaboration led by Laura Samples, MD Fred Hutch Cancer Center UW Medicine Newsroom ashpublications.org/blood/article-…

Dr. StevenBairMD CU Lymphoma Program contributed to a multicenter study published in Haematologica about real-world outcomes of lonca in R/R DLBCL. pubmed.ncbi.nlm.nih.gov/39540227/ #lymsm

Our CU Lymphoma Program lead Dr. manalikamdar just had an abstract published of the final results from the TRANSCEND trial of liso-cel in R/R MCL. #lymsm #tcellrx sciencedirect.com/science/articl…

Our CU Lymphoma Program junior faculty Dr. Ajay Major, MD, MBA conducted a qualitative study on NLPHL perspectives from patients and their care partners, now published. cc GLOW: Global nLPHL One Working Group #lymsm tandfonline.com/doi/full/10.10…

New #research from #CUAnschutz suggests that memories held within blood stem cells may trigger the often-disabling symptoms of autoimmune disease that flare up over a person’s lifetime. news.cuanschutz.edu/news-stories/d…

Congratulations to Dr. Timothy Voorhees, MD, MSCR et al. on this important study, and many thanks for the opportunity to contribute patients from CU Anschutz Division of Hematology CU Lymphoma Program. #lymsm cc Cassandra Duarte

Dr. Ajay Major, MD, MBA CU Lymphoma Program (as well as incoming CU Anschutz Division of Hematology lymphoma faculty Dr. Cassandra Duarte) contributed to a large study of patients with Hodgkin lymphoma refractory or intolerant to BV and checkpoint inhibitors. #lymsm cc Timothy Voorhees, MD, MSCR

It was a pleasure to speak with manalikamdar, Gloria Iacoboni & Paolo Strati (MD Anderson Cancer Center) recently, who shared interesting insights into the sequencing of therapies in R/R NHL, including DLBCL, MCL & FL! Watch here 👉 ow.ly/6e7S50VqsqU #LymSM #ImmunoOnc #HemOnc

Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 CAR-T: If these favorable preliminary results in patients with MCL are replicated in larger multicenter trials, this platform could emerge as a new standard therapy in B-cell malignancies. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

6 year follow up of acala +/- Obin vs SOC obi/Clb presented ASH 2023 finally in print. Obinutuzumab often left out of regimen, yet the combo is extremely effective and depth of response matters! ashpublications.org/blood/article/…

Our CU Lymphoma Program lead Dr. manalikamdar contributed to the ELEVATE-TN trial, now published Blood Journal. #leusm #lymsm cc CU Cancer Center CU Anschutz Division of Hematology

Our CU Lymphoma Program faculty Dr. Ajay Major, MD, MBA contributed to a multicenter study of venetoclax in relapsed/refractory Waldenstrom macroglobulinemia, now published Blood Cancer Journal. #lymsm pmc.ncbi.nlm.nih.gov/articles/PMC12…

2nd myeloid cancers post CD19 CAR Nicolas GAZEAU - 539 pts, all B-NHL - 2-yr cumulative risk t-MN: 4.5% (10% at 4 yrs!) - ⬆️ MCV & high-grade ICANS risk factors for t-MN - 86% of t-MN had pre-CAR mutations Important retrospective study for #tcellrx. #lymsm nature.com/articles/s4137…

Elated to be joining the ASH Clinical Research Training Institute (CRTI) in 2025! Eager to work on our research program utilizing PROs to improve treatment decision-making in indolent lymphomas. Deeply grateful to my mentors Drs. Jamie L. Studts, PhD & manalikamdar. #lymsm

You made my day James !!! Thank you !!!

It's always a pleasure to catch up w/ Manali Kamdar (manalikamdar) of CU Cancer Center 😄 At #ASCO25, she provided insight into research exploring how to optimize post-CAR T-cell monitoring in patients with #lymphoma receiving liso-cel: 🎥 ow.ly/eiKO50W3RXw #LYMsm #DLBCL

Navigating CART for Lymphoma in 2025 - great session at #EHA2025 with manalikamdar Kai Rejeski and the OG Prof Zinzani #CART #lymsm

>1500 trial & CIBMTR pts who received liso-cel: - 96-97% of CRS events were before D+15 - 88-95% ICANS before D+15 - no G5 CRS/ICANS after D+15 Do we really need a full 30 days of monitoring after liso-cel? manalikamdar #lymsm #tcellrx #18ICML